Latest Hotspot

Atsena Therapeutics Announces Positive Early Results in Phase 1/2 XLRS Gene Therapy Study

10 May 2024
3 min read

Atsena Therapeutics, a company at the clinical stage specializing in gene therapy, released encouraging early results from the initial group of the LIGHTHOUSE study. This Phase I/II clinical trial investigates the effects of subretinal injection of ATSN-201 in treating X-linked retinoschisis (XLRS). Atsena is dedicated to harnessing the transformative capacity of genetic medicine to either reverse or prevent vision loss.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 应用程序

描述已自动生成

ATSN-201 employs AAV.SPR, a unique capsid developed by the company, to deliver therapeutic gene expression to photoreceptors in the central retina, bypassing the surgical complications associated with foveal detachment. The LIGHTHOUSE trial is testing ATSN-201 in males aged 6 years and older diagnosed with XLRS due to RS1 gene mutations. This disorder involves the splitting of retinal layers, known as schisis, leading to decreased visual acuity that glasses cannot correct and resulting in progressive vision loss, ultimately causing blindness. Approximately 30,000 males in the United States and Europe are affected by XLRS, for which no approved treatments currently exist.

In the initial group of the LIGHTHOUSE trial, two out of three participants exhibited significant schisis resolution starting eight weeks post-treatment. Continued improvement was noted up to week 24, which is the most recent follow-up period reported. Importantly, resolution of the schisis cavities was observed both within and beyond the areas of the subretinal injections, suggesting that AAV.SPR is effectively dispersing from the initial sites of injection, aligning with the anticipated properties of this novel capsid designed for lateral spread.

Preliminary signs of efficacy were also detected through microperimetry assessments, where enhancements in function mirrored the structural resolutions observed. In one case, a patient experienced up to a 14 dB improvement, with 38 spots showing enhancements of more than 7 dB. The FDA regards an enhancement of 7 dB or more across at least five predetermined spots as clinically significant.

Furthermore, ATSN-201 was well received by all participants in the first group of the XLRS study, with no serious adverse effects reported. These findings suggest for the first time that subretinal injections can be administered safely in patients with extensive retinal schisis.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of May 9, 2024, there are 7 investigational drugs for the XLRS1 targets, including 1 indications, 8 R&D institutions involved, with related clinical trials reaching 4, and as many as 399 patents.

ATSN-201 is a gene therapy targeting the XLRS1 gene for the treatment of Retinoschisis. With its current highest phase being Phase 1/2, this drug holds promise in the field of biomedicine and may offer a potential treatment option for individuals with this congenital eye disorder.

图形用户界面, 文本, 应用程序

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 10
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 10
10 May 2024
May 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
What ADC-related progress will Medilink Therapeutics reveal at the ASCO conference?
Hot Spotlight
2 min read
What ADC-related progress will Medilink Therapeutics reveal at the ASCO conference?
10 May 2024
Medilink Therapeutics will present preliminary results from the first human clinical Phase 1 trial of YL202 for the treatment of locally advanced or metastatic non-small cell lung cancer and breast cancer (NCT05653752).
Read →
What Does Blinatumomab Do?
Pharma Pioneer
3 min read
What Does Blinatumomab Do?
10 May 2024
Blinatumomab, sold under the brand name Blincyto, is a breakthrough cancer treatment developed by Amgen Inc.
Read →
EyeDNA Therapeutics Presents Promising 2-Year Phase 1/2 Study Results on HORA-PDE6b Therapy for Retinitis Pigmentosa at ARVO
Latest Hotspot
3 min read
EyeDNA Therapeutics Presents Promising 2-Year Phase 1/2 Study Results on HORA-PDE6b Therapy for Retinitis Pigmentosa at ARVO
10 May 2024
EyeDNA Therapeutics Reveals Encouraging Two-Year Results at ARVO for its Phase 1/2 Study on HORA-PDE6b Genetic Treatment in Retinitis Pigmentosa Patients with Dual Mutations in PDE6b.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.